DE2347326A1 - Neue pharmazeutische zubereitungen - Google Patents
Neue pharmazeutische zubereitungenInfo
- Publication number
- DE2347326A1 DE2347326A1 DE19732347326 DE2347326A DE2347326A1 DE 2347326 A1 DE2347326 A1 DE 2347326A1 DE 19732347326 DE19732347326 DE 19732347326 DE 2347326 A DE2347326 A DE 2347326A DE 2347326 A1 DE2347326 A1 DE 2347326A1
- Authority
- DE
- Germany
- Prior art keywords
- mesoridazine
- hypnotic
- treatment
- sleep
- sleep disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 229960000300 mesoridazine Drugs 0.000 title abstract description 14
- 230000000147 hypnotic effect Effects 0.000 title abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 208000019116 sleep disease Diseases 0.000 claims abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000007958 sleep Effects 0.000 abstract description 13
- 206010052804 Drug tolerance Diseases 0.000 abstract description 3
- 206010019133 Hangover Diseases 0.000 abstract description 3
- 230000026781 habituation Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 239000008298 dragée Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- CRJHBCPQHRVYBS-UHFFFAOYSA-N mesoridazine besylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 CRJHBCPQHRVYBS-UHFFFAOYSA-N 0.000 description 5
- 229960003664 mesoridazine besylate Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- -1 1-methyl-2-piperidyl Chemical group 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 206010037249 Psychotic behaviour Diseases 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1403172 | 1972-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2347326A1 true DE2347326A1 (de) | 1974-03-28 |
Family
ID=4397345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732347326 Pending DE2347326A1 (de) | 1972-09-26 | 1973-09-20 | Neue pharmazeutische zubereitungen |
Country Status (5)
| Country | Link |
|---|---|
| AU (1) | AU6063773A (enExample) |
| BE (1) | BE805236A (enExample) |
| DE (1) | DE2347326A1 (enExample) |
| NL (1) | NL7313037A (enExample) |
| ZA (1) | ZA737592B (enExample) |
-
1973
- 1973-09-20 DE DE19732347326 patent/DE2347326A1/de active Pending
- 1973-09-21 NL NL7313037A patent/NL7313037A/xx unknown
- 1973-09-24 BE BE135977A patent/BE805236A/xx unknown
- 1973-09-24 AU AU60637/73A patent/AU6063773A/en not_active Expired
- 1973-09-26 ZA ZA00737592*A patent/ZA737592B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6063773A (en) | 1975-03-27 |
| NL7313037A (enExample) | 1974-03-28 |
| BE805236A (fr) | 1974-03-25 |
| ZA737592B (en) | 1975-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0188810B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Verhinderung oder Behandlung posttraumatischer Nervenschäden nach unfallbedingten Rückenmarks- und/oder Gehirntraumen | |
| DE2813480A1 (de) | Arzneimittel-depotpraeparat vom mehrfacheinheitsdosen-typ | |
| CH647150A5 (de) | Zubereitung, enthaltend ein tranquillans und ein propiophenon. | |
| DE69926804T2 (de) | Vorrichtungen zur behandlung und diagnose des restless leg syndroms | |
| EP0040325A1 (de) | Verwendung von Adenosinderivaten zur Herstellung eines Psychopharmakons | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| AT389226B (de) | Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung | |
| DE69612510T2 (de) | Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode | |
| DE1492253A1 (de) | Verfahren zur Herstellung von Tabletten mit protrahierter Wirkung | |
| DE3490399T1 (de) | Pharmazeutische Präparate mit appetitmindernder Wirkung und Verfahren zu deren Herstellung | |
| EP1513533A2 (de) | Pharmazeutische wirkstoffkombination sowie deren verwendung | |
| DE60015098T2 (de) | 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| DE2347326A1 (de) | Neue pharmazeutische zubereitungen | |
| DE2755017C2 (enExample) | ||
| DE3228351A1 (de) | Arzneimittel zur behandlung von schlafstoerungen | |
| EP0315197B1 (de) | Oral anzuwendende Arzneiform zur einmal täglichen Behandlung der Hypertonie mit Diltiazemhydrochlorid | |
| DE2260384B2 (de) | Oral zu applizierendes Corticosteroid-Präparat | |
| DE3930282A1 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
| DE2501649C3 (de) | Thiophen-2-carbonsäuresalz des Papaverins, Verfahren zu seiner Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2831728C2 (de) | Arzneimittel zur Behandlung von Kopfschmerzen | |
| EP0930884B1 (de) | Chronische verwendung von lorazepam und diphenhydramin | |
| DE3404316C1 (de) | Lorazepam-haltiges Schlafmittel | |
| DE1617336C2 (de) | Arzneimittel gegen Angina pectoris | |
| DE69122480T2 (de) | Verwendung von Phenyläthanolaminotetralinen zur Herstellung eines antidepressiven und Antistress-Arzneimittels |